Trial intelligence / Profile preview

Antazoline vs Propafenone in Paroxysmal Atrial Fibrillation

NCT05720572Phase 4

Key facts

Status: Recruiting
Start: Sep 2019
Primary completion: Sep 2025
Countries: 1
Sponsor: Centrum Medyczne Kształcenia Podyplomowego
Modality: Small Molecules

Drugs: antazoline
Conditions: Atrial fibrillation (AFib)

Overview

Phase 4, randomised, double-blind trial of antazoline in Atrial fibrillation (AFib) (2 arms), sponsored by Centrum Medyczne Kształcenia Podyplomowego. Primary endpoint: Conversion of atrial fibrillation to sinus rhythm at 3 hours. Started Sep 2019; status: recruiting.

Design

2 arms

Study design: RandomizedDouble-blind

Antazoline
Antazoline IV boluses
Propafenone
Propafenone IV boluses

Who it enrols

Adult patients with paroxysmal atrial fibrillation lasting less than 48 hours, without heart failure (LVEF >= 50%), significant valvular disease, or recent ischemic events.

Endpoints

Primary

Conversion of atrial fibrillation to sinus rhythm3 hours

Secondary

Time to conversion of atrial fibrillation to sinus rhythm3 hours
Serious adverse events3 hours
Disturbances of atrioventricular conduction3 hours
Hypotension < 90mmHg3 hours
Prolongation of QTc3 hours

Beyond the preview

Go deeper on NCT05720572.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05720572.